GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Plans » Marpai Inc (NAS:MRAI) » Definitions » COGS-to-Revenue

Marpai (Marpai) COGS-to-Revenue : 0.66 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Marpai COGS-to-Revenue?

Marpai's Cost of Goods Sold for the three months ended in Mar. 2024 was $4.87 Mil. Its Revenue for the three months ended in Mar. 2024 was $7.39 Mil.

Marpai's COGS to Revenue for the three months ended in Mar. 2024 was 0.66.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Marpai's Gross Margin % for the three months ended in Mar. 2024 was 34.04%.


Marpai COGS-to-Revenue Historical Data

The historical data trend for Marpai's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marpai COGS-to-Revenue Chart

Marpai Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
- - 0.72 0.70 0.65

Marpai Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.66 0.64 0.65 0.66 0.66

Marpai COGS-to-Revenue Calculation

Marpai's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=24.239 / 37.155
=0.65

Marpai's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=4.871 / 7.385
=0.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Marpai  (NAS:MRAI) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Marpai's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 4.871 / 7.385
=34.04 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Marpai COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Marpai's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Marpai (Marpai) Business Description

Traded in Other Exchanges
N/A
Address
5701 East Hillsborough Avenue, Suite 1417, Tampa, FL, USA, 33610-5428
Marpai Inc operates as a health plan company. It uses A.I. to predict and help prevent costly events for its members, and in turn, lower its clients' health care costs. It offers a health plan services system that addresses the problems of healthcare past and enables companies to provide healthcare to employees. The company generates the majority of its revenue from the United States.
Executives
Yaron Eitan director 65 CHALLENGER ROAD, RIDGEFIELD PARK NJ 07660
Damien Lamendola director, 10 percent owner 5701 EAST HILLSBOROUGH AVENUE, SUITE 1417, TAMPA FL 33610-5428
Edmundo Gonzalez director, officer: CEO, Secretary and Director C/O SELWAY CAPITAL ACQUISITION CORP., 74 GRAND AVENUE, 2ND FLOOR, ENGLEWOOD NJ 07631
Sagiv Shiv director
Vincent Kane director 5701 EAST HILLSBOROUGH AVENUE, SUITE 1417, TAMPA FL 33131
Ronnie Brown officer: Chief Operating Officer 5701 EAST HILLSBOROUGH AVENUE, SUITE 1417, TAMPA FL 33610-5428
Mohsen Moazami director C/O ASTREA ACQUISITION CORP., 55 OCEAN LANE DRIVE, APT. 3021, KEY BISCAYNE FL 33149
Lutz Finger officer: See Remarks 5701 EAST HILLSBOROUGH AVENUE, SUITE 1417, TAMPA FL 33610
Yoram Bibring officer: Chief Financial Officer C/O SELWAY ACQUISITION CORPORATION, 66 FORD ROAD, SUITE 230, DENVILLE NJ 07834
Jane Cavalier director 5701 EAST HILLSBOROUGH AVENUE, SUITE 1417, TAMPA FL 33610-5428
Diclaudio Colleen director 456 SEATON STREET, LOS ANGELES CA 90013
Art Hoath officer: Chief Revenue Officer 5701 EAST HILLSBOROUGH AVENUE, SUITE 1417, TAMPA FL 33610-5428
Gonen Antebi director 5701 EAST HILLSBOROUGH AVENUE, SUITE 1417, TAMPA FL 33610-5428
Eli David other: See footnote (1) 5701 EAST HILLSBOROUGH AVENUE, SUITE 1417, TAMPA FL 33131